psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345678910111213...1314»
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    IID.01 – Daring to be different: innovative approaches to psychiatry (Corner 1 (Hall X1) [IN-PERSON]) -  Oct 13, 2022 - Abstract #ECNP2022ECNP_1219;    
    Boehringer Ingelheim’s precision psychiatry approach will be introduced through discussion of the link between emotional dysregulation—a key feature across multiple diagnostically distinct conditions—and amygdala hyperactivity. The COMPASS Pathways approach will be demonstrated with reference to its proprietary formulation of psilocybin (COMP360), which has been successfully used with psychological support to create a new pathway to mental well-being for patients with treatment-resistant depression.Following the company presentations, participants will be encouraged to engage in discussion of the potential benefits and challenges associated with both approaches to innovating the field of psychiatry and their respective clinical implications.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial completion, Enrollment change, Trial primary completion date:  Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) (clinicaltrials.gov) -  Sep 22, 2022   
    P=N/A,  N=66, Completed, 
    COMP360 25mg was generally well-tolerated supporting further development of COMP360 for TRD. Recruiting --> Completed | N=150 --> 66 | Trial primary completion date: May 2022 --> Aug 2022
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  The use of psilocybin for treatment-resistant depression (Pubmed Central) -  Sep 7, 2022   
    In the phase 2 study of COMPASS Pathways, the psilocybin-COMP360 treatment led to a rapid response and remission as early as three weeks following the treatment for around one third of participants...Further research will reveal whether it will be granted a license to treat treatment-resistant depression in the near future. There remains an urgent need for novel treatments for those who do not respond to current antidepressant therapies.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial primary completion date:  Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder (clinicaltrials.gov) -  Aug 3, 2022   
    P2,  N=12, Active, not recruiting, 
    These data provide further evidence on the therapeutic mechanisms of psilocybin and escitalopram in the treatment of depression. Trial primary completion date: Jun 2022 --> Sep 2022
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial completion:  Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy (clinicaltrials.gov) -  Jul 25, 2022   
    P2,  N=16, Completed, 
    Trial primary completion date: Jun 2022 --> Sep 2022 Active, not recruiting --> Completed
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment closed:  Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder (clinicaltrials.gov) -  Apr 12, 2022   
    P2,  N=12, Active, not recruiting, 
    There was a rapid reduction of depressive symptoms for the 25mg arm with a significant treatment difference compared with the 1mg arm from the day after COMP360 psilocybin administration up to week 6. Recruiting --> Active, not recruiting
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy (clinicaltrials.gov) -  Feb 22, 2022   
    P2,  N=20, Active, not recruiting, 
    EudraCT (https://www.clinicaltrialsregister.eu/) number: 2018-000978-30. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial initiation date:  Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy (clinicaltrials.gov) -  Apr 27, 2021   
    P2,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting Initiation date: Dec 2020 --> May 2021
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] The Effects of COMP360 (psilocybin formulation) on Cognitive function: Results from a randomized, Placebo-Controlled Trial in Healthy Participants () -  Apr 13, 2021 - Abstract #ASCP2021ASCP_132;    
    For Rapid Visual Information Processing, a measure of sustained attention, there were trends indicating better performance on average for COMP360 10 mg and 25 mg by day 29 compared to baseline, but no difference was observed for COMP360 10 mg and 25 mg when compared to placebo, nor between COMP360 25 mg and 10 mg. For Spatial Working Memory there were trends indicating better performance on average for COMP360 25 mg by day 29 compared to baseline, but no difference was observed for COMP360 10 mg and 25 mg when compared to placebo, nor between COMP360 25 mg and 10 mg.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. (clinicaltrials.gov) -  Mar 3, 2021   
    P2,  N=12, Recruiting, 
    For Spatial Working Memory there were trends indicating better performance on average for COMP360 25 mg by day 29 compared to baseline, but no difference was observed for COMP360 10 mg and 25 mg when compared to placebo, nor between COMP360 25 mg and 10 mg. Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Initiation date: Nov 2020 --> Mar 2021 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) (clinicaltrials.gov) -  Mar 3, 2021   
    P2,  N=15, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Initiation date: Nov 2020 --> Mar 2021 | Trial primary completion date: Jan 2021 --> Jan 2022 Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Initiation date: Nov 2020 --> Mar 2021 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment open:  Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder (clinicaltrials.gov) -  Mar 2, 2021   
    P2,  N=12, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Initiation date: Nov 2020 --> Mar 2021 | Trial primary completion date: Jan 2021 --> Jan 2022 Not yet recruiting --> Recruiting